Tang Ya Ling, Jiang Jian Hong, Wang Shuang, Liu Zhu, Tang Xiao Qing, Peng Juan, Yang Yong-Zong, Gu Hong-Feng
Key Lab for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South China, Hengyang, 421001, People's Republic of China.
Chuanshan College, University of South China, Hengyang, 421001, People's Republic of China.
PLoS One. 2015 Apr 10;10(4):e0123685. doi: 10.1371/journal.pone.0123685. eCollection 2015.
Chronic stress is an important risk factor for atherosclerotic diseases. Our previous studies have shown that chronic unpredictable mild stress (CUMS) accelerates atherosclerosis and up-regulates TLR4/NF-κB expression in apoE-/- mice. However, TLR4/NF-κB signaling whether directly contributes to the development of atherosclerosis in CUMS mice is unclear. We hypothesized that the interference of TLR4/NF-κB can ameliorate CUMS-induced inflammation and atherosclerosis in apoE-/- mice.
ApoE-/- mice were exposed to 12 weeks CUMS. Ad-siRNA TLR4 was given by tail vein injection (10 μl/mouse, every 5 days), and PDTC (an inhibitor of NF-κB) was given by intraperitoneal injection (60 mg/kg, once a day). Plasma corticosterone concentrations were determined by solid-phase 125I radioimmunoassay. Atherosclerosis lesions in aortic sinuses were evaluated and quantified by IMAGEPRO PLUS. Western blotting was used to detect the expression of TLR4, NF-κB, and IL-1β in aortas of the mice. Plasma lipid profiles, IL-1β, TNF-α, and MCP-1 were measured by ELISA.
Our results indicated that CUMS apoE-/- mice treatment with siRNA TLR4 significantly decreased atherosclerosis and down-regulated TLR4, NF-κB, and inflammatory cytokines. PDTC also remarkably reduced atherosclerosis and the levels of IL-1β, TNF-α and MCP-1 in plasma. However, Treatment with siRNA TLR4 or PDTC had no effect on plasma corticosterone levels, and lipid profiles.
TLR4/NF-κB pathway may participate in CUMS-induced atherosclerosis through activation of proinflammatory cytokines in apoE-/- mice. Our data may provide a new potential therapeutic target for prevention of CUMS -induced atherosclerosis.
慢性应激是动脉粥样硬化性疾病的重要危险因素。我们之前的研究表明,慢性不可预测性轻度应激(CUMS)可加速动脉粥样硬化,并上调载脂蛋白E基因敲除(apoE-/-)小鼠体内Toll样受体4(TLR4)/核因子κB(NF-κB)的表达。然而,TLR4/NF-κB信号通路是否直接促进CUMS小鼠动脉粥样硬化的发展尚不清楚。我们推测,干扰TLR4/NF-κB可改善CUMS诱导的apoE-/-小鼠炎症和动脉粥样硬化。
将apoE-/-小鼠暴露于12周的CUMS环境中。通过尾静脉注射给予腺病毒介导的小干扰RNA(Ad-siRNA)TLR4(10 μl/只小鼠,每5天一次),并通过腹腔注射给予NF-κB抑制剂吡咯烷二硫代氨基甲酸盐(PDTC,60 mg/kg,每天一次)。采用固相125I放射免疫分析法测定血浆皮质酮浓度。通过IMAGEPRO PLUS软件评估并量化主动脉窦处的动脉粥样硬化病变。采用蛋白质免疫印迹法检测小鼠主动脉中TLR4、NF-κB和白细胞介素-1β(IL-1β)的表达。采用酶联免疫吸附测定法检测血浆脂质谱、IL-1β、肿瘤坏死因子-α(TNF-α)和单核细胞趋化蛋白-1(MCP-1)。
我们的结果表明,用siRNA TLR4处理CUMS apoE-/-小鼠可显著减轻动脉粥样硬化,并下调TLR4、NF-κB和炎性细胞因子。PDTC也显著减轻了动脉粥样硬化以及血浆中IL-1β、TNF-α和MCP-1的水平。然而,用siRNA TLR4或PDTC处理对血浆皮质酮水平和脂质谱没有影响。
TLR4/NF-κB通路可能通过激活apoE-/-小鼠体内的促炎细胞因子参与CUMS诱导的动脉粥样硬化。我们的数据可能为预防CUMS诱导的动脉粥样硬化提供一个新的潜在治疗靶点。